Abstract IA011: The epigenetic-based liquid biopsy odyssey of bedside pancreatic cancer diagnostics

Abstract

Abstract Pancreatic cancer (PC), often diagnosed at an advanced stage, urgently requires innovative early detection methods to improve patient outcomes. Presently, there is no approved screening method for pancreas cancer and its high-risk individuals (HRIs), as existing techniques rely on costly and invasive imaging modalities, which face challenges in detecting interval cancers. This study presents an innovative approach that utilizes liquid biopsy technology combined with blood-based DNA methylation biomarkers—ADAMTS1, BNC1, and LRFN5. These biomarkers demonstrate a remarkable 94% diagnostic accuracy for early-stage PC detection, providing a transformative strategy in precision medicine. In line with precision medicine principles, the potential application of this liquid biopsy-based DNA methylation panel for monitoring HRIs offers a promising path toward personalized surveillance. The creation of an affordable bedside test with exceptional diagnostic accuracy has the potential to revolutionize early detection strategies for PCs. Identifying early curable stage PC through this liquid biopsy technique aligns perfectly with precision medicine, promising increased patient survival. If successfully integrated into routine healthcare, early detection could significantly advance the fight against pancreatic cancer, paving the way for more effective and patient-centric diagnostic approaches. Citation Format: Nita Ahuja. The epigenetic-based liquid biopsy odyssey of bedside pancreatic cancer diagnostics [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2):Abstract nr IA011.